A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Clinical Epidemiology
June 15, 2021
Fascinating confirmation of null hypotheses including bleeding complications and survival in a Pennsylvanian cohort study, despite the easily predictable previous PCI, hock, and IABP prevalence in the emergency group. The statistical model is elaborate and complex. Perhaps a randomized trial could now be justified!
June 11, 2021
A useful detailed review (or state-of-the-art article) on revascularisation in extracardiac vascular stenoocclusive atheromatosis.
May 11, 2021
The updated version of an expert viewpoint on resources for management of acute aortic syndrome in the United States is presented. The esteemed authors advance the position of positive volume–outcome relationship for surgery for acute De Bakey I and II (ATAAD).
January 10, 2021
An interesting retrospective study on the efficacy of the the US screening program for aortic aneurysmal disease in the abdomen. The discussion on the detective importance of clinical examination being complementary to sonography is pertinent.
December 4, 2020
A brief and readable editorial on the United Kingdom prespective on the global impact of the pandemic to the delivery of cardiovascular care, attempting a semi-quantitative economic appraisal of the problem.
November 28, 2020
A large RCT with results somewhat supportive of considering a NOAC in the place of warfarin for post operative surgical patients. The study will be weighed against healthcare economical aspects.
November 28, 2020
A relatively recent, open-access, brief viewpoint on the utility of screening for thoracic aortic pathologies.
November 17, 2020
A latge RCT of the first myosin inhibitor in severe chronic heart failure: somewhat difficult to interpret results, as deaths were slightly higher in the intervention group while there was no 'significant' benefit in cardiovascular deaths.
October 26, 2020
Within the limitations of a meta-analysis, a useful work advancing that PCI may have a hitherto masked or hidden mortality